Onco Actu du 27 février 2017

	1. Biologie
New structural studies reveal workings of a molecular pump that ejects cancer drugs [The Rockefeller University] MRP1 is part of a large family of pumps involved in many physiological processes throughout the body. Since other members of this family also eject drugs, this work has medical relevance beyond MRP1. “Ultimately, we hope these and other structures like them could serve as templates for designing chemotherapy drugs the pumps don’t recognize, or inhibitors that block them,” Johnson says.
Discovery of distinct cell subtypes around tumors helps explain why pancreatic cancer is so hard to treat [CSHL] This discovery of heterogeneity in the fibroblast portion of the stroma in pancreatic cancer opens up the field to a host of new possibilities.
The Cell Atlas [MIT Technology Review] Biology’s next mega-project will find out what we’re really made of. Availability: 5 years.
	3.1 Tabac
NHS 'tobacco free' campaign launched by Public Health England [BBC News] Only one in 10 hospitals enforces a smoking ban outside health service buildings, and Public Health England (PHE) wants all hospitals to offer help to quit as part of patients' treatment.
	5.2 Pharma
J&J leads $25M Series A in targeted radiotherapy startup [FierceBiotech] The funding will support a phase 1a of Fusion’s antibody-targeted radiotherapy, beyond which the Canadian biotech plans to run a proof-of-concept trial in non-small cell lung cancer (NSCLC).
	5.2.1 Pharma - Partenariats
Sanofi and Lonza to build new $285 million Swiss biologics facility [Reuters] French drugmaker Sanofi and Swiss manufacturer Lonza will invest 270 million euros ($285 million) in a new large-scale biologics facility that will produce monoclonal antibodies by 2020.
	5.2.3 Pharma - économie
Pharma heads write to Congress... and put foot in mouth [Forbes] What is worrisome is that the pharma leaders' endorsement of protectionist policies fits in a pattern of addressing their companies' innovation woes by relying on strategies that produce none of it—typically financial ploys, lobbying, and regulatory gimmicks.
	5.3.4 Traitements - AMM (FDA, EMA)
REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation [Celgene] The new indication expands the availability of REVLIMID® across the disease continuum of multiple myeloma.
FDA Approves Lenalidomide as Maintenance Therapy for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant [ESMO] The approval is based on two randomised, controlled trials, CALGB 100104 and IFM 2005-02.
	6.10 Politiques
Cancer patients could be significantly disadvantaged by Brexit, say experts [The Guardian] “We need to take every opportunity to remind the UK government that cancer patients and cancer research could be significantly disadvantaged, unless great care is deployed in the negotiations of the legal and economic frameworks which will govern the UK’s relationship with the EU beyond Brexit.”
	6.10.1 Politiques (USA)
Cancer can bankrupt its victims. Obamacare was designed to stop that. [Vox] Cancer bills have been a leading cause of personal bankruptcy in the US, and a third of survivors report ongoing cancer-related financial problems — a common reason many skipped health care they may have needed.
Cancer patients, survivors fear GOP efforts to dismantle the Affordable Care Act [Washington Post] As the battle over the law escalates, cancer patients and survivors are among the most vocal of groups raising alarms about the GOP’s repeal effort.
	6.4 Médico-éco
Cancer treatment is changing and coverage must change with it [The Hill] With every study, we're learning more about why treatments help some patients and not others — it's a complete revolution in managing lung cancer, and it is entirely dependent upon this molecular profiling that allows matching the right drug to the right patient.
	6.7 DMP, Big Data & applis
NHS misplaced half a million patient documents [BBC News] An investigation is under way, focusing on the estimated 2,500 patients who may have been adversely affected and need further medical checks.